The Ranter

EP02: The Cure Heist. How Drugs Get Priced

• Markus Grant • Season 1 • Episode 2

Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.

0:00 | 19:34

In 2015, Martin Shkreli's Turing Pharmaceuticals raised the price of Daraprim from $13.50 to $750 a tablet overnight. Same molecule. Same factory. The only thing that changed was who owned the company.

Markus Grant maps the system behind it: one drug, five different prices, and a pharmacy benefit manager in the middle that negotiates a rebate off the list price and keeps a cut. Three of them run about 80 percent of the prescriptions in the country. Then the four doors around the middleman.

Key receipts:
- $13.50 to $750: Daraprim, overnight (New York Times, Sept 2015)
- About 80 percent: prescription claims run by the three biggest PBMs (FTC, July 2024)
- 132: patents granted around Humira, an unchanged molecule (I-MAK)
- $577 billion: what 14 large drug companies spent on buybacks and dividends from 2016 to 2020, $56 billion more than on R&D (House Oversight, 2021)
- $751 million: health sector lobbying in 2024, the top sector (OpenSecrets)

Receipts and case file: theranter.com/case-file/the-cure-heist
Newsletter: newsletter.theranter.com
Watch on YouTube: youtube.com/@TheRanterOfficial